Tolero Pharmaceuticals in the Daily Herald
April 29, 2018
This concept is based on the idea that drugs can be more effective once doctors know whether or not they will be right for specific patients. “It’s the right drug for the right patient for the right disease,” said Kelly Slone, president and CEO of BioUtah.
Tolero has already seen success testing this type of drug for treating acute myeloid leukemia. As Tolero Pharmaceuticals CEO David Bears said, “Now what we’re trying to do is develop a drug, and we say, ‘this drug isn’t for everybody, but we have a way to tell whether it’s for you.’ I want to see my discoveries move into something that can help people, that’s motivating to me, thinking I can help people with something I’ve discovered in our lab.”
Click here to read the full article
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
